prioirty review

Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Tue, 02/11/20 - 10:28 am
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer